VERTEX PHARMACEUTICALS INC / MA
VRTXPharma & biotechvrtx.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 3, 2026
Next reportFebruary 10, 2027after close · forecast 4.771 $/share
Revenue
$3.44B
▲ +11.8% vs prior year YoY
Net income
$653.60M
▼ -39.6% vs prior year YoY
EPS
2.56$
▼ -39.0% vs prior year YoY
Net margin
19.0%
▼ -16.2 pp vs prior year YoY
Revenue▲ +11.8%
Margins (% of revenue)GrossOperatingNet
Net income▼ -39.6%
EPS▼ -39.0%
Financial statements
View 10-Q filed November 3, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $2.91B | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B | $3.33B | $3.44B | ▲ +11.8% |
| Gross profit | $2.49B | $2.41B | $2.56B | $2.66B | $2.72B | $2.59B | $2.84B | $2.91B | ▲ +9.5% |
| Operating income | $1.03B | $630.10M | $1.15B | $1.19B | $1.21B | $1.14B | $1.25B | $712.90M | ▼ -39.9% |
| Net income | $913.00M | $646.30M | $1.03B | $1.08B | $1.19B | $1.03B | $1.10B | $653.60M | ▼ -39.6% |
| R&D | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 2.49 $ | 3.99 $ | 4.20 $ | — | 4.02 $ | 4.31 $ | 2.56 $ | ▼ -39.0% |
| Margins (% of revenue) | |||||||||
| Gross | 85.5 % | 86.9 % | 86.3 % | 86.5 % | 85.4 % | 86.8 % | 85.3 % | 84.7 % | ▼ -1.8 pt |
| Operating | 35.2 % | 22.7 % | 38.8 % | 38.6 % | 37.8 % | 38.1 % | 37.4 % | 20.7 % | ▼ -17.8 pt |
| Net | 31.4 % | 23.3 % | 34.8 % | 35.2 % | 37.3 % | 34.5 % | 33.0 % | 19.0 % | ▼ -16.2 pt |
| Balance sheet | |||||||||
| Assets | $22.53B | $22.88B | $24.04B | $24.86B | $25.64B | $26.48B | $27.42B | $32.74B | ▲ +31.7% |
| Liabilities | $6.12B | $6.38B | $6.86B | $7.54B | $6.98B | $7.12B | $7.18B | $11.83B | ▲ +56.8% |
| Equity | $16.41B | $16.50B | $17.18B | $17.32B | $18.67B | $19.36B | $20.25B | $20.91B | ▲ +20.7% |
| Cash | $4.57B | $4.67B | $4.97B | $4.94B | $5.08B | $5.49B | $6.14B | $4.98B | ▲ +0.8% |
| Capital | |||||||||
| Shares outstanding | 256.79M | 256.80M | 256.39M | 253.72M | 254.03M | 253.81M | 253.46M | 253.54M | ▼ -0.1% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.